# Phase I/II Study of Nab-paclitaxel and Gemcitabine Followed by AG-mFOLFOX in Patients With Metastatic Pancreatic Adenocarcinoma

> **NCT02504333** · PHASE1,PHASE2 · COMPLETED · sponsor: **Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)** · enrollment: 168 (actual)

## Conditions studied

- Metastatic Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** nab-paclitaxel
- **DRUG:** gemcitabine
- **DRUG:** m-FOLFOX
- **DRUG:** nab-paclitaxel
- **DRUG:** gemcitabine

## Key facts

- **NCT ID:** NCT02504333
- **Lead sponsor:** Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2021-04
- **Final completion:** 2021-04
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2023-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02504333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02504333, "Phase I/II Study of Nab-paclitaxel and Gemcitabine Followed by AG-mFOLFOX in Patients With Metastatic Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02504333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*